Summary:
Vismodegib (GDC-0449), a small molecule Hedgehog Pathway Inhibitor, was well tolerated in patients with solid tumors and showed promising efficacy in advanced basal cell carcinoma in a Phase I trial. The purpose of the present study was to determine routes of elimination and extent of vismodegib metabolism, including assessment and identification of metabolites in plasma, urine and feces.
Published Date: 20th May, 2011
Author Richard A. Graham, Bert L. Lum, Glenn Morrison, Ilsung Chang, Karin Jorga, Brian Dean, Young Shin, Qin Yue, Teresa Mulder, Vikram Malhi, Minli Xie, Jennifer A. Low, C.E.C.A Hop,
Download

Please complete the following for access to the download

Name:
Email:
 

Click to see more publications